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RESEARCH
Persistent polypharmacy and fall injury risk: 
the Health, Aging and Body Composition Study
Lingshu Xue1,2, Robert M. Boudreau1, Julie M. Donohue2, Janice C. Zgibor3, Zachary A. Marcum4, 
Tina Costacou1, Anne B. Newman1, Teresa M. Waters5 and Elsa S. Strotmeyer1* 
Abstract 
Background: Older adults receive treatment for fall injuries in both inpatient and outpatient settings. The effect of 
persistent polypharmacy (i.e. using multiple medications over a long period) on fall injuries is understudied, particu-
larly for outpatient injuries. We examined the association between persistent polypharmacy and treated fall injury risk 
from inpatient and outpatient settings in community-dwelling older adults.
Methods: The Health, Aging and Body Composition Study included 1764 community-dwelling adults (age 
73.6 ± 2.9 years; 52% women; 38% black) with Medicare Fee-For-Service (FFS) claims at or within 6 months after 
1998/99 clinic visit. Incident fall injuries (N = 545 in 4.6 ± 2.9 years) were defined as the initial claim with an ICD-9 fall 
E-code and non-fracture injury, or fracture code with/without a fall code from 1998/99 clinic visit to 12/31/08. Those 
without fall injury (N = 1219) were followed for 8.1 ± 2.6 years. Stepwise Cox models of fall injury risk with a time-vary-
ing variable for persistent polypharmacy (defined as ≥6 prescription medications at the two most recent consecutive 
clinic visits) were adjusted for demographics, lifestyle characteristics, chronic conditions, and functional ability. Sen-
sitivity analyses explored if persistent polypharmacy both with and without fall risk increasing drugs (FRID) use were 
similarly associated with fall injury risk.
Results: Among 1764 participants, 636 (36%) had persistent polypharmacy over the follow-up period, and 1128 
(64%) did not. Fall injury incidence was 38 per 1000 person-years. Persistent polypharmacy increased fall injury risk 
(hazard ratio [HR]: 1.31 [1.06, 1.63]) after adjusting for covariates. Persistent polypharmacy with FRID use was associ-
ated with a 48% increase in fall injury risk (95%CI: 1.10, 2.00) vs. those who had non-persistent polypharmacy without 
FRID use. Risks for persistent polypharmacy without FRID use (HR: 1.22 [0.93, 1.60]) and non-persistent polypharmacy 
with FRID use (HR: 1.08 [0.77, 1.51]) did not significantly increase compared to non-persistent polypharmacy without 
FRID use.
Conclusions: Persistent polypharmacy, particularly combined with FRID use, was associated with increased risk for 
treated fall injuries from inpatient and outpatient settings. Clinicians may need to consider medication management 
for FRID and other fall prevention strategies in community-dwelling older adults with persistent polypharmacy to 
reduce fall injury risk.
Keywords: Persistent polypharmacy, Treated fall injury, Medicare, Medication, Falls, FRID, Geriatrics
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Background
Medication use may be associated with falls and fall inju-
ries among older adults. Nearly one third of community-
dwelling U.S. adults over 65 years old experience falls 
annually, with the percent increasing to 50% in adults 
Open Access
*Correspondence:  strotmeyere@edc.pitt.edu
1 Department of Epidemiology, Graduate School of Public Health, 
University of Pittsburgh, 130 N Bellefield Avenue, Suite 300, Pittsburgh, PA 
15213, USA
Full list of author information is available at the end of the article
Page 2 of 10Xue et al. BMC Geriatrics          (2021) 21:710 
over 80 years old [1, 2]. Of those who fall, 5% incur seri-
ous injuries such as fractures, joint dislocation, and 
head trauma [3]. Each year, nearly 3 million older adults 
receive treatment for fall injuries in emergency depart-
ments (ED), and around 800,000 are hospitalized for fall 
injuries [4]. In the US, fall injuries resulted in approxi-
mately $668 billion in medical expenses during 2015 [5]. 
One potentially modifiable risk factor for fall injury is 
multiple medication use, commonly referred to as poly-
pharmacy [6]. In previous studies related to fall injury, 
polypharmacy has been defined according to the num-
ber of medications measured in a single short period (e.g. 
90 days) [7–9]. However, older adults may vary in use of 
medications over time [10, 11]. Newly diagnosed acute or 
chronic conditions may prompt an increase in the num-
ber of medications, while deprescribing and poor adher-
ence may reduce the number [11]. Considering whether 
polypharmacy was persistent or transient over time may 
be important to identify older adults at high risk of fall 
injury.
The role of persistent polypharmacy in fall injury 
remains largely unexamined. In a few previous stud-
ies based on claims data, persistent polypharmacy was 
defined as use of multiple medications for more than 
6 months in a year follow-up; however many older adults 
have polypharmacy for longer duration and addition-
ally these studies did not consider fall injury risks [12, 
13]. Studies examining polypharmacy persisting longer 
than 1 year are strongly needed. One study of adults 
aged 60-64 years found that polypharmacy at two time 
points 5 years apart doubled the decline in chair rise 
speed compared to polypharmacy only at one time point 
[14], suggesting persistent polypharmacy for more than 
1 year may be associated with reduced physical func-
tion. However, this study did not account for comorbid 
conditions or factors related to physical function in the 
analysis, and did not investigate fall injury outcomes 
[14]. To fill this gap, our study defined persistent polyp-
harmacy as use of multiple medications in two consecu-
tive years based on our previous studies in this cohort 
[15, 16], and examined its association with fall injury. In 
addition, fall-risk increasing drugs (FRID, i.e. sedatives 
and hypnotics, neuroleptics and antipsychotics, anti-
depressants, benzodiazepines, and opioids) specifically 
appear to be strongly related to fall injuries rather than 
polypharmacy alone [17–19]. Whether persistent poly-
pharmacy with FRID use is associated with a higher fall 
injury risk compared to polypharmacy without FRID use 
has not been well investigated. Understanding the role 
of persistent polypharmacy in fall injury is important for 
evaluating the appropriateness of deprescribing and pro-
viding a tailored intervention to reduce fall injury risk in 
older adults. Therefore, our objective was to determine 
whether persistent polypharmacy, both with and without 
FRID use, is associated with an increased risk of fall inju-
ries treated in inpatient and outpatient settings among 




The Health, Aging and Body Composition (Health ABC) 
Study is a prospective cohort study designed to inves-
tigate if changes in body composition act as a common 
pathway by which multiple diseases affect morbidity, 
disability, and risk of mortality in community-dwelling 
older adults [20]. This study included 3075 participants 
(48.4% male, 41.6% black) aged 70–79 years at baseline 
(1997/1998) [20]. They were recruited from a random 
sample of Medicare beneficiaries in Memphis, Tennes-
see (TN), and Pittsburgh, Pennsylvania (PA), and all age-
eligible black community residents in these areas [21]. 
Participants were excluded if they: 1) reported difficulty 
with walking one-quarter of a mile or climbing 10 steps 
without resting, or difficulty with performing mobility-
related activities of daily living; 2) had life-threatening 
cancers and received active treatment in the past 3 years; 
or 3) had plans of leaving the area within 3 years [21]. The 
institutional review boards at the participating institu-
tions approved the study protocol, and written informed 
consent was obtained before testing and data collection 
[21]. The exclusion criteria for this analysis included 1) 
missing a 2000/01 clinic visit (N = 671) since Medicare 
data was only linked for those participants; 2) lacking 
linked Medicare FFS Parts A and B claim data (N = 28); 
3) not having FFS coverage at 1997/98 baseline clinic 
visit (N = 456) or within 6 months after the baseline visit 
(N = 20); and 4) having fall injury (N = 90) or ending FFS 
coverage (N = 46) before 1998/99 clinic visit when per-
sistent polypharmacy was measured (Fig. 1). After exclu-
sions, the analytic sample included 1764 participants.
Primary independent variables
The primary independent variable was a time-varying 
indicator of persistent polypharmacy. We defined persis-
tent polypharmacy as use of ≥6 prescription medications 
at both of the two most recent consecutive annual clinic 
visits based on the established Health ABC definition 
for the long-term use of fall-related medications [6, 15]. 
Compared to some definitions for polypharmacy, which 
define it as ≥5 medications in short periods, we used a 
cut-point of ≥6 medications due to known increase in 
the number of medications taken as age increases, espe-
cially considering that polypharmacy was measured as 
time-varying in our cohort with more than 8 years fol-
low-up. Non-persistent polypharmacy was defined as use 
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of ≥6 medications only at one visit or use of <6 medica-
tions at both of the two most recent consecutive visits. 
Participants with intermittent polypharmacy (i.e. using 
≥6 medications at some clinic visits but never having 
persistent polypharmacy during the entire study period, 
N = 174) were included only in the sensitivity analyses to 
distinguish the effect of persistent polypharmacy from 
that of polypharmacy at a single time point. FRID include 
antiepileptic drugs, hypnotics/sedatives drugs, antipsy-
chotics, antidepressants, benzodiazepines, and opioids 
based on previous reviews for FRID and the 2015 updates 
of the Beers’ criteria (supplementary Table  S1) [17–19]. 
Antihypertensives and anticholinergic drugs (except for 
antidepressants and antipsychotics) were not included 
due to non-significant association with fall risk shown 
in previous published papers in the Health ABC Study 
[16, 22]. A time-varying FRID use indicator was created 
for sensitivity analyses based on if participants used ≥1 
FRID at most recent (short-term) or both (long-term) 
of the two most recent consecutive visits since a previ-
ous publication in our study showed both short-term and 
long-term use of FRID were related to increased fall risk 
[15] (Fig. 2).
Medication information was collected at clinic visits in 
1997/98, 1998/99, 1999/2000, 2001/02, 2002/03, 2004/05, 
2006/07, and 2007/08 and coded according to the Iowa 
Drug Information System [23]. Participants brought 
all medications taken during the 2 weeks before the 
clinic visit. Trained researchers transcribed medication 
information from the containers. Non-prescription 
medications such as over-the-counter medications, 
and herbal and dietary supplements are not commonly 
included in the definition of polypharmacy [6] so we did 
not include these. Since medication information was not 
collected in 2000/01, 2003/04, and 2005/06, we used the 
method of last observation carried forward (LOCF) to 
estimate the missing data. Sensitivity analyses also were 
conducted in the data without the estimation by LOCF.
Outcome measure
The primary outcome was incident treated fall injury 
from the 1998/99 clinic visit to 12/31/08, identified using 
Fee-for-Service (FFS) Part A and Part B Medicare claim 
datasets which included inpatient, outpatient, physi-
cian/supplier, and carrier (claims from non-institutional 
providers) files [21]. The Medicare claims allowed fall 
injury events treated in inpatient and outpatient settings 
(e.g. inpatient hospitals, outpatient clinics, and emer-
gency departments) to be collected if participants did 
not attend clinic visits or provide self-report data [21]. 
ICD-9 E-codes (E880-888) which describe the “mecha-
nism of injury” were used to ascertain falls, and ICD-9 
billing codes were used to identify injuries and fractures 
[21]. Incident fall injury was defined as the first event 
with 1) an ICD-9 fall E-code (E880-888) and non-fracture 
injury, 2) a vertebral fracture code (805-806) with a fall 
E-code, or 3) a non-vertebral fracture code (800-804, 
807-829) with/without a fall E-code [21]. We excluded all 
Fig. 1 Flow chart displaying selection of study participants for analysis. FFS: Fee-For-Service
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traumatic injuries (e.g., motor vehicle accidents), inten-
tional injuries, and pathologic injuries [21]. We compared 
a subset of Medicare fall injuries to the self-reported fall 
injuries with medical records to validate our diagnoses 
code algorithm which showed excellent agreement with 
the medical records [21]. We excluded vertebral fractures 
without fall codes in our algorithm since only 50% of ver-
tebral fractures in Medicare claims were fall-related when 
validated with medical records [21]. Participants were 
followed until the first occurrence of a fall injury, the end 
of FFS coverage, loss to follow-up, death, or through the 
end of 2008 when Medicare claims were last collected for 
the study.
Covariates
All covariates were measured at the 1997/98 clinic visit 
unless noted otherwise. Self-reported demographic vari-
ables included age, sex, race (white or black), education 
(<high school (HS), HS graduate, or postsecondary), 
and study site (Memphis or Pittsburgh) [21]. Height was 
measured using a stadiometer and weight was measured 
on a calibrated balance beam scale [21]. The baseline 
BMI was calculated using the formula of weight (kilo-
grams) divided by height (meters) squared [21]. Lifestyle 
factors included alcohol consumption (> 1 drink/week), 
self-reported physical activity (kcal/kg per week spent 
walking, climbing stairs, and exercise), and self-reported 
smoking status (current, past, never; at the 1999/2000 
clinic visit) [24].
Participants self-reported cardiovascular disease (i.e. 
bypass or coronary artery bypass graft, carotid endarter-
ectomy, myocardial infarction, angina pectoris, or con-
gestive heart failure), cerebrovascular disease (i.e. stroke 
or transient ischemic attack), poor vision (poor eye-
sight, cataract, glaucoma, retinal disease, and/or macular 
degeneration), history of falls, knee pain for > 1 month, 
and leg pain when walking. We defined diabetes as self-
reported physician diagnosis, use of hypoglycemic medi-
cation, or fasting glucose ≥126 mg/dL (47.0 mmol/L) 
after an 8-h fast [25]. Diagnosed and/or treated hyper-
tension (“hypertension” hereafter) was defined through 
a study-based definition as self-reported hypertension 
with use of any antihypertensive medications, or sit-
ting systolic blood pressure ≥ 140 mmHg or/and sitting 
diastolic blood pressure ≥ 90 mmHg [21, 22]. Depressive 
symptoms were assessed based on the Center for Epide-
miologic Studies Depression Scale (CES-D) [26]. Cogni-
tive function was measured by the Modified Mini-Mental 
State Examination (3MSE) score [27]. Poor renal function 
was defined as cystatin C level > 1 mg/dL [28]. Sensory 
nerve impairment was defined as insensitivity to 1.4-g 
monofilament at the 2000/01 clinic visit [29]. We also 
included physical performance as 6-m usual gait speed 
[30].
Statistical analyses
We compared baseline characteristics for those with vs. 
without fall injury using t-tests for normally distributed 
Fig. 2 Timeline and illustrations for persistent polypharmacy. PP: persistent polypharmacy. FRID: fall risk increasing drugs
Page 5 of 10Xue et al. BMC Geriatrics          (2021) 21:710  
variables, Wilcoxon rank-sum tests for non-normally dis-
tributed variables, and Chi-squared tests for categorical 
variables. Because the status of persistent polypharmacy 
varied over time, we reported the event rate of persis-
tent polypharmacy in the follow-up as well as fall injury 
incidence rates in the periods of persistent polypharmacy 
and non-persistent polypharmacy. We also included the 
indicators of persistent polypharmacy as a time-varying 
predictor in multivariable Cox proportional hazards 
(Cox PH) regression to estimate fall injury risk from the 
1998/99 clinic visit. Baseline covariates described above 
were time-independent and added to the model in a 
stepwise manner. To minimize collinearity, additional 
covariates except for age, sex, and race were subsequently 
removed at a P > 0.10 and if the effect of persistent poly-
pharmacy was not modified > 10% [31]. In sensitivity 
analyses, we included a combination time-varying vari-
able for persistent polypharmacy with and without FRID 
use in models, defined as: persistent polypharmacy with 
FRID use; persistent polypharmacy without FRID use; 
non-persistent polypharmacy with FRID use; non-persis-
tent polypharmacy without FRID use [19]. Analyses were 
done in the cohort including 174 participants with inter-
mittent polypharmacy (N = 1764). In addition to the cut-
point of 6 medications in the primary analyses, we used 2 
to 5 and 7 to 10 as alternative cut-points to define persis-
tent polypharmacy (e.g. ≥2 vs. < 2 medication, ≥3 vs. < 3 
medications, ≥4 vs. < 4 medications, ≥5 vs. < 5 medica-
tions, etc.) and repeated the analyses [7–9]. All analyses 
were repeated without LOCF to check for consistency 
of results. No violation of PH assumption was detected. 
Analyses were performed using SAS, version 9.4 (SAS 
Institute, Inc., Cary, NC).
Results
At the 1997/98 clinic visit, participants were aged 
73.6 ± 2.9 years, 53% were women, and 37% were black. 
In the analytic sample (N = 1764), participants were fol-
lowed for 8.0 ± 3.1 years from the 1998/99 clinic visit. 
Among 1764 participants, 36% (N = 636) had persistent 
polypharmacy, and 64% (N = 1128) did not. The rate 
of persistent polypharmacy was 179 events per 1000 
person-years. Incident fall injuries occurred in 31% of 
1764 participants (N = 545, 414 fracture and 131 non-
fracture) over 4.6 ± 2.9 years following the 1998/99 clinic 
visit. Those without fall injury (N = 1219) were followed 
for 8.1 ± 2.6 years. The incident rate of fall injury was 
38 per 1000 person-years in the follow-up, with 50 per 
1000 person-year during the period of persistent polyp-
harmacy, and 36 per 1000 person-year during the period 
of non-persistent polypharmacy. Participants with fall 
injury were older and more likely to be women, white, 
and a high school graduate compared to those without 
fall injury (Table  1). Participants with fall injuries were 
more likely to have lower BMI, higher 3MSE scores, and 
self-report a fall in the past 12 months. No difference 
was found between those with and without fall injuries 
Table 1 Baseline characteristics and medication use over time 
by incident fall injury status (N = 1764)
CES-D Center for Epidemiologic Studies Depression Scale score, range is 0 to 
60; a score of 16 points or more is considered depressed, 3MSE Modified Mini-
Mental State Examination, range is 0 to 100; lower scores represent lower levels 
of mental competency, FRID Fall risk increasing drugs
a P < 0.05, b < 0.01 for fall injury vs. no fall injury
Characteristics, Mean ± SD or 
N (%)
Fall injury (N = 545) No Fall 
injury 
(N = 1219)
Age, years 73.9 ± 3.0a 73.5 ± 2.8
Women, N (%) 357 (65.5%)b 561 (46.0%)
Black race, N (%) 154 (28.3%)b 508 (41.7%)
Pittsburgh site, N (%) 243 (44.6%)a 464 (38.1%)
Body mass index, kg/m2 26.7 ± 4.8b 27.5 ± 4.7
Current smoker, N (%) 39 (7.2%) 116 (9.5%)
Alcohol > 1 drink/week, N (%) 257 (47.9%) 609 (50.7%)
≥ High school graduate, N (%) 440 (81.6%)b 872 (72.4%)
Fall history, N (%) 144 (26.6%)a 242 (19.9%)
Hypertension, N (%) 311 (57.0%) 695 (57.1%)
Cardiovascular disease, n (%) 91 (16.9%) 208 (17.3%)
Cerebrovascular disease, n (%) 45 (8.3%) 78 (6.5%)
Diabetes, N (%) 107 (19.7%) 264 (21.8%)
Cystatin C > 1.0, N (%) 236 (44.0%) 556 (46.0%)
Poor vision, N (%) 12 (2.2%) 25 (2.1%)
CES-D score 4.6 ± 5.2 4.5 ± 5.2
3MSE score 91.7 ± 6.9b 90.3 ± 8.1
Knee or leg pain, N (%) 181 (33.3%) 379 (31.2%)
1.4 g Monofilament insensitivity, 
N (%)
207 (38.8%) 421 (35.1%)
6-m Gait speed, m/second 1.2 ± 0.2 1.2 ± 0.2
Number of medications
 1998/99 clinic visit 3.5 ± 2.7a 3.0 ± 2.6
 1999/00 clinic visit 3.7 ± 2.9b 3.3 ± 2.7
 2001/02 clinic visit 4.3 ± 3.1b 3.7 ± 2.7
 2002/03 clinic visit 4.5 ± 3.2b 4.0 ± 2.9
 2004/05 clinic visit 5.1 ± 3.3a 4.6 ± 3.2
 2006/07 clinic visit 5.7 ± 3.3a 5.0 ± 3.5
 2007/08 clinic visit 5.9 ± 3.7a 5.3 ± 3.6
Use of ≥1 FRID, N (%)
 1998/99 clinic visit 126 (23.1%)b 201 (16.5%)
 1999/00 clinic visit 142 (26.0%)b 220 (18.1%)
 2001/02 clinic visit 157 (28.8%)b 252 (20.7%)
 2002/03 clinic visit 158 (29.0%)b 270 (22.1%)
 2004/05 clinic visit 122 (22.4%)b 232 (19.0%)
 2006/07 clinic visit 109 (20.0%)b 211(17.3%)
 2007/08 clinic visit 102 (18.7%)b 196 (16.1%)
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for diabetes, cardiovascular disease, cerebrovascular dis-
ease, CES-D scores, poor vision, knee or leg pain, gait 
speed, 1.4-g monofilament insensitivity, or cystatin C 
level > 1 mg/dL. No differences were seen in the results 
of descriptive analyses between the samples including 
(N = 1764) and excluding those with intermittent polyp-
harmacy (N = 1590).
In the univariate Cox model, participants with persis-
tent polypharmacy had an increased fall injury risk than 
those with non-persistent polypharmacy (HR: 1.29 [1.05, 
1.59]). After adjusting for age, sex, race, study site, alco-
hol use, BMI, 1.4-g monofilament insensitivity, fall his-
tory, the HR of persistent polypharmacy was 1.31 (1.06, 
1.63) (Table 2). Compared to participants who had non-
persistent polypharmacy without FRID use, those with 
persistent polypharmacy and FRID use had a significantly 
increased fall injury risk (HR: 1.48 [1.10, 2.00]). Com-
pared to non-persistent polypharmacy without FRID use, 
HRs for persistent polypharmacy without FRID use (HR: 
1.22 [0.93, 1.60]) and non-persistent polypharmacy with 
FRID use (HR: 1.08 [0.77, 1.51] did not show an associa-
tion with fall injury risk. Results of sensitivity analyses 
were consistent with the primary analyses after includ-
ing those with intermittent polypharmacy in the referent 
group (Supplementary Table S2). Most of the results were 
consistent with the primary analyses when cut-points of 
7 to 10 medications were used to define persistent poly-
pharmacy. In addition, there was also a noticeable jump 
in the HR for fall injury when going from a cut-point of 
5 to a cut-point of 6. This finding supports the criteria of 
6 prescription medications as an appropriate cut-point 
to distinguish the effect of persistent polypharmacy [6]. 
(Supplementary Table  S3). The results without LOCF 
were consistent with primary analyses (Supplementary 
Table S2).
Discussion
In this prospective study of community-dwelling older 
adults with Medicare FFS, we found an increased risk of 
treated fall injury with persistent polypharmacy, particu-
larly when combined with use of FRID. In our findings, 
older adults with persistent polypharmacy and FRID use 
had nearly 50% higher fall injury risk compared to those 
who had non-persistent polypharmacy without FRID 
use. To our knowledge, our study was the first to suggest 
a synergic effect of polypharmacy and FRID on the risk 
of fall injuries treated in both inpatient and outpatient 
settings.
The contribution of FRID use to the association of per-
sistent polypharmacy and fall injury risk has not been 
well investigated. Previous studies in community-dwell-
ing older adults showed that polypharmacy was associ-
ated with inpatient treated fall injuries after accounting 
for the confounding effect of FRID, but did not report 
the contribution of FRID use to the association [9, 32, 
33]. However, our study observed a possible synergic 
effect from polypharmacy and FRID use on fall injury 
risk. The varying definitions for FRID use makes it diffi-
cult to compare across previous work and is a limitation 
in the field. Our FRID definition was modified based on 
the Beer’s Criteria commonly used in the US [17–19]; 
while previous studies used medication lists from their 
Table 2 Adjusted hazard ratios of persistent polypharmacy and FRID on fall injury in the primary analysis
Education (<high school (HS), HS graduate, or postsecondary), self-reported physical activity (kcal/kg per week spent walking, climbing stairs and exercise), self-
reported smoking status (current, past, never), alcohol > 1 drink/week, self-reported cardiovascular diseases, poor vision, knee pain for > 1 month, leg pain when 
walking, diagnosed and/or treated hypertension and diabetes, CES-D score, Modified Mini-Mental State Examination (3MSE) scores, cystatin C level > 1 mg/dL, gait 
speed over 6 m were added to the model in a stepwise manner and subsequently removed at a P > 0.10
FRID Fall risk increasing drugs, PP Persistent polypharmacy
Model 1 Model 2
HR (95% CI) p-value HR (95% CI) p-value
PP vs. non-PP 1.31(1.06,1.63) 0.014
Joint-effect of PP and FRID use (reference: Non-PP without FRID use)
 PP with FRID use 1.48(1.10,2.00) 0.010
 PP without FRID use 1.22(0.93,1.60) 0.155
 Non-PP with FRID use 1.08(0.77,1.51) 0.659
Body mass index, per 1 kg/m2 0.98(0.96,1.00) 0.060 0.98(0.96,1.00) 0.061
Age, per 1 year 1.03(1.00,1.07) 0.046 1.03(1.00,1.07) 0.048
Women vs. men 2.09(1.71,2.56) <.0001 2.08(1.70,2.54) <.0001
Blacks vs. whites 0.64(0.51,0.79) <.0001 0.64(0.51,0.80) <.0001
Pittsburgh site vs. Memphis site 1.54(1.27,1.87) <.0001 1.55(1.27,1.88) <.0001
Fall history vs. no history 1.29(1.05,1.59) 0.015 1.29(1.05,1.59) 0.017
1.4 g Monofilament insensitivity 1.22(1.01,1.47) 0.040 1.22(1.01,1.47) 0.042
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national fall prevention guidelines or STOPP/Fall criteria 
which is widely used in European countries [9, 32–34]. 
Our definition was tailored to the Health ABC popula-
tion, excluding antihypertensives and some anticholin-
ergics due to non-significant association with fall risk 
shown in previous published Health ABC findings [16, 
22]. The other major difference in our study vs. previous 
studies is the inclusion of outpatient fall injuries (i.e. falls 
and fall injuries treated in outpatient clinics, emergency 
departments, or other outpatient settings) which are esti-
mated to constitute around 57% of fall injuries requiring 
medical care [35]. Our results may suggest older adults 
with polypharmacy and FRID use were at higher risk of 
fall injuries leading to treatment in outpatient settings in 
addition to inpatient hospital settings [9, 32, 36]. Future 
studies need to carefully consider the appropriateness of 
certain medication classes in the FRID definition for their 
populations, as no standard definition exists.
Persistent polypharmacy is most likely the consequence 
of chronic multi-morbidities [36, 37]. Older adults with 
multi-morbidities may be more likely to receive any 
treatment, which could increase the likelihood of receiv-
ing treatment for fall injuries as well, especially for less 
severe injuries [38, 39]. In addition, older adults with 
multi-morbidities who also use FRID may experience 
increased fall risks related to chronic conditions such as 
osteoarthritis, vision loss, and peripheral nerve impair-
ment [40–42], as well as from effects of FRID use such 
as sedation, dizziness, and postural sway [15, 43–45]. The 
adverse effects of FRID use may be more likely in older 
adults with multi-morbidities and/or polypharmacy pos-
sibly due to increasing pharmacodynamic sensitivity to 
FRID or high risk of drug-drug interactions [15, 43]. Fur-
ther studies are needed to replicate our findings in other 
samples of older adults to assess the joint effect of polyp-
harmacy and FRID use in fall injury.
A growing number of observational studies, including 
our study, showed polypharmacy appears to be a risk fac-
tor for fall injury in community-dwelling older adults [9, 
32, 44]. Interventions are needed to reduce the risk for 
fall injuries in older adults with polypharmacy living in 
the community. However, several randomized trials dem-
onstrated that single intervention targeting withdraw-
ing medications, including FRID use, did not reduce fall 
injury risk significantly among older adults [46, 47]. Dis-
crepant results between observational studies and rand-
omized trials possibly suggest that single intervention for 
medications is insufficient for reducing fall risk as obser-
vational studies are not able to account for unmeasured 
factors, such as the severity of chronic conditions that is 
correlated with polypharmacy and increases fall injuries 
as well. In addition, previous randomized trials showed 
the difficulty of implementing medication withdrawal 
interventions among older adults using multiple medica-
tions [48, 49]. Besides medication withdrawal interven-
tions, other evidence-based recommendations for fall 
prevention include exercise and multifaceted interven-
tions which are customized based on initial assessments 
in various components, such as balance, gait, vision, pos-
tural blood pressure, medication, environment, cogni-
tion, and psychological health [50]. Studies have shown 
that community-dwelling older adults who present in 
ED with a fall often did not receive fall risk assessment 
and relevant interventions in accordance with guide-
lines, representing a missed opportunity to address their 
fall risk profile [51, 52]. Some randomized trials further 
supported that customized fall prevention interven-
tions including medication management initiated in ED 
services reduced the risk of subsequent fall injuries by 
43-65% [53, 54]. Therefore, clinicians in outpatient set-
tings, especially in ED may need to consider tailoring 
fall prevention strategies in multiple aspects, in addition 
to medication management for community older adults 
with polypharmacy, such as promoting exercise, wearing 
safe shoes, improving safety in the home environment, 
and additional preventative efforts related to chronic 
multi-morbidities (e.g. diabetes, cardiovascular diseases, 
and dementia).
Tailoring fall interventions by demographic groups 
may need to be considered in clinical practice to improve 
the effectiveness of fall prevention. Our study, in accord-
ance with previous studies, demonstrated that women 
and White individuals were more likely to have fall inju-
ries compared to men and Black individuals, respectively 
[55–58]. Sex differences in fall injury risk, especially 
higher fracture risk in women, are well-established [55, 
59]. Racial differences in fall injury risk may reflect dif-
ferences in chronic diseases in late life, such as higher 
prevalence of osteoporosis in older White populations 
[60]. In our population, education level was not associ-
ated with risk of fall injury after adjusting for race in the 
final model, suggesting race group explained the associa-
tion of education level and fall injury. Further studies are 
needed to delineate the underlying mechanisms for lower 
fall injury risk in non-White older adults and evaluate the 
effectiveness of fall interventions in racially diverse aging 
populations of men and women.
Our study has several strengths. A follow-up for 
nearly 8 years allowed examining of the temporal 
relationship between polypharmacy and incident fall 
injuries. The combined variable of persistent poly-
pharmacy and FRID use over time may improve our 
understandings of the role of FRID in the relation-
ship between polypharmacy and fall injury risk. Our 
focus on persistent polypharmacy may provide more 
comprehensive insights of real-life medication use 
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compared to previous studies that focused on polyp-
harmacy at a single time point [9, 32, 61]. Our medi-
cation inventory was based on participants’ use rather 
than prescription fill or pharmacy databases which 
may be less accurate for actual use. We used a vali-
dated aggregate diagnoses code algorithm to identify 
treated fall injuries in both inpatient and outpatient 
settings compared to previous studies including only 
inpatient fall injuries based on hospital admissions [8, 
9, 32]. In addition, our participants had more chronic 
conditions and a higher prevalence and incidence of 
fall injury compared to older adults ≤70 years old [62], 
allowing us to study older adults at high risk for both 
polypharmacy and fall injuries. Moreover, the cohort 
study data combined with Medicare FFS claims ena-
bled us to adjust for a rich set of health conditions 
and factors compared to other studies that only used 
claims-based covariates.
A limitation of our study is that medication inven-
tories were done annually though not done at cer-
tain clinic visits and the LOCF method was used to 
estimate the missing data from annual visits. The 
prevalence of persistent polypharmacy may be over-
estimated since LOCF may misclassify those without 
persistent polypharmacy as with persistent polyphar-
macy. Imputation of medication use is not an ideal 
approach in older populations due to the relationship 
of missing data at clinic visits and poor health status 
[63]. However, our results showed no changes when 
analyzing the data without LOCF. Annual medication 
inventories did not allow us to address non-adherence 
issues which are prevalent among older adults with 
polypharmacy [64]. The fall injuries in our study were 
medically treated; therefore, less serious, non-treated 
fall injuries were not ascertained. We also could not 
observe complete claims for those with dual eligibil-
ity for Medicaid and/or veteran affairs health insur-
ance. Thus, the rate of treated fall injury events may 
be underestimated. Our results should be reevaluated 
in non-PA or TN residents since reporting E-code 
may not be mandatory in some states [21]. Finally, our 
population is community-dwelling older adults with 
Medicare FFS eligibility who met the inclusion criteria 
of the Health ABC cohort and had at least two clinic 
visits to measure persistent polypharmacy. These 
inclusion criteria likely resulted in a healthier cohort 
compared to the general Medicare FFS population 
since those missing clinic visits generally had older 
age, more mobility limitation, and more cognitive 
impairment [63]. Also, our results may be not repre-
sentative of older adults with other health care cover-
age or in non-community based settings such as skilled 
nursing facility (SNF) settings.
Conclusions
Our study showed persistent polypharmacy was associ-
ated with increased fall injury risk treated in both inpa-
tient and outpatient settings, particularly when combined 
with FRID use. These findings suggest that future studies 
should consider targeting medication use such as FRID 
use and other fall prevention efforts, such as altering 
behaviors or living environment, and tailoring interven-
tions by sex and racial groups in older adults with per-
sistent polypharmacy to decrease treated fall injuries not 
only in inpatient but also in outpatient settings.
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